Peptone, Owkin, Capital Rx
ImmunOs Therapeutics Raises $74M in Series B Financing
ImmunOs Therapeutics AG, a Schlieren (Zurich Area), Switzerland-based biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, raised $74 million in Series B financing.
The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq.
ImmunOs Therapeutics leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The company has identified specific HLA molecules known to activate the immune system and is utilizing these HLA molecules as the backbone of novel therapies capable of stimulating both the innate and the adaptive immune systems of cancer patients to eliminate tumor cells.
ImmunOs Therapeutics Raises $74M in Series B Financing
ImmunOs Therapeutics AG, a Schlieren (Zurich Area), Switzerland-based biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, raised $74 million in Series B financing
Ariceum Therapeutics Raises EUR 25M in Series A Funding
Ariceum Therapeutics, a Berlin, Germany-based biotech company, raised EUR25M in Series A funding.
Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap who also co-led the financing that was joined by Pureos Bioventures. Ipsen transferred assets, and all corresponding rights into the company in late 2021. In conjunction with the financing, Karin Kleinhans of EQT Life Sciences, Per Samuelsson of HealthCap and Martin Münchbach of Pureos Bioventures will join Ariceum’s board of directors together with Eduardo Bravo, CEO of EBAC, who has been elected as chairman of the board. he company intends to use the funds to further develop its lead asset and proprietary peptide derivative, satoreotide.
Led by CEO Manfred Rüdiger, Ariceum Therapeutics is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers.
Ariceum Therapeutics Raises EUR 25M in Series A Funding - FinSMEs
Ariceum Therapeutics, a Berlin, Germany-based biotech company, raised EUR25M in Series A funding
French AI biotech startup Owkin gets $80-million shot from Bristol Myers Squibb to accelerate drug development
Parisian AI biotech unicorn Owkin has brought in $80 million as it partners with the US-based pharmaceutical giant Bristol Myers Squibb on drugs trials. The new partnership could be transformational for patient outcomes and scientific progress, making machine learning solutions an integral part of the clinical trial process.
The $80 million will be split between a Series B-1 equity round, led by Bristol Myers Squibb, and up-front fees for clinical trials for cardiovascular drugs using Owkin’s technology. The fresh funding brings the company’s total raised to over $300 million.
Owkin will use the investment to support its data generation strategy in multiple therapeutic areas with a strong focus on multimodal and rich biological data, including the most advanced spatial single-cell omics technologies.
The startup had partnered with pharmaceutical giant Sanofi last year. The partnership brought an investment of $180 million for Owkin to make it to the unicorn club.
Founded in 2016, the startup aims to bring new drugs to the market faster via more precise and effective trials. It allows doctors, medical researchers, and pharmaceutical companies to identify new drug candidates, and enhance clinical trials while drawing on health data from usually siloed sources such as hospitals across the U.S. and Europe.
French AI biotech startup Owkin gets $80-million shot from Bristol Myers Squibb to accelerate drug development - Tech.eu
Owkin will use the investment to support its data generation strategy in multiple therapeutic areas with a strong focus on multimodal and rich biological data
London’s Charm Therapeutics raises $50 million as it takes on cancer treatment
Charm Therapeutics has raised $50 million in a Series A funding round co-led by F-Prime Capital and OrbiMed. The capital is slated to be used to further the company’s ambitions of transforming structure-based drug discovery, namely via its proprietary “DragonFold AI” technology.
Founded in 2021 by David Baker, Ph.D., and Laksh Aithani, Charm is using deep-learning models via its proprietary platform, DragonFold, to predict the co-crystal structure of a protein-ligand complex based on a protein’s primary sequence and the ligand’s chemical structure. In doing so, these models help discover and develop new medicines aimed at treating previously hard-to-drug targets including certain forms of cancer.
Alongside F-Prime Capital and OrbiMed’s lead, Charm Therapeutics’ $50 million Series A round also saw the support of General Catalyst, Khosla Ventures, Braavos, Grep VC, and Axial.
London’s Charm Therapeutics raises $50 million as it takes on cancer treatment - Tech.eu
Using AI-power 3D deep-learning models to discover and develop new drug treatments, London-based Charm Therapeutics has raised $50 million in a Series A funding round
London startup Peptone gets $40-million booster to focus on drugs for disordered proteins
Around half the proteins in the human body, including many that are crucial in health and disease, have some regions that do not fold neatly into fixed structures and thus cannot be accurately predicted from the underlying genetic sequences. Due to this lack of information, many drug development programmes fail because they aim rigidly designed drugs against these disordered targets.
Founded in 2018, London-based Peptone has combined atom-level physical protein analysis techniques to create an accurate representation of disordered proteins and protein regions, predicting the best way to target them with drugs.
The biotech startup has now raised $40 million in funding to speed up its protein drug discovery process. The funding will drive operations at its advanced facility in Bellinzona, Switzerland, to solve complex and problematic intrinsically disordered protein structures at scale. It will also support Peptone’s algorithmic engine, which runs on a supercomputer built in exclusive collaboration with NVIDIA in Keflavik, Iceland.
The round was led by F-Prime Capital and Bessemer Venture Partners, with participation from Walden Catalyst Ventures and existing investors, including Hoxton Ventures and dRX Capital, the venture arm of Novartis.
The company will be able to initiate its own pipeline of unique targets in a range of diseases, including inflammation, cancer and diabetes, and begin experimenting with a completely novel class of medicines — structurally dynamic drugs based on disordered proteins from Bellinzona.
London startup Peptone gets $40-million booster to focus on drugs for disordered proteins - Tech.eu
London-based Peptone has combined atom-level physical protein analysis techniques to create an accurate representation of disordered proteins and protein regions, predicting the best way to target them with drugs
Synklino Closes EUR 29.8M Series A Funding
Synklino, a Copenhagen, a Denmark-based biotech company developing new drugs for the treatment of chronic viral infections, raised EUR 29.8M in Series A funding.
The company is owned by renowned Nordic funds and institutional investors Eir Ventures, The Danish Growth Fund and PKA as well as approximately 70 private shareholders.
Led by CEO Thomas Kledal, Synklino is a biotech company developing therapies against chronic viral infections.
The company intends to use the funds to advance its drug candidate SYN002 for the treatment of Cytomegalovirus (CMV), into both ex vivo and in vivo Phase 1 clinical trials and generate safety and efficacy data establishing a solid foundation for expanding its pipeline, and widening the strategic options for further value creation.
Active infection and accumulation of a high virus load in immunosuppressed patients leads to a variety of CMV diseases, including organ rejection, developmental and neurological complications, and can be fatal. CMV has a major impact on morbidity and mortality during transplantation and increases transplant costs by up to 50% due to long-term hospitalizations and difficult courses of treatment. The treatment of CMV therefore represents a large unmet medical need. No currently marketed or pipeline drugs can cure CMV, and current drugs pose a risk of developing resistance.
Synklino Closes EUR 29.8M Series A Funding - FinSMEs
Synklino, a Copenhagen, a Denmark-based biotech company developing new drugs for the treatment of chronic viral infections, raised EUR 29.8M in Series A funding
Mineralys Therapeutics Closes $118M Series B Financing
Mineralys Therapeutics, Inc., a Philadelphia, PA-based clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension, closed a $118m Series B financing.
The round was led by RA Capital Management and Andera Partners with participation from new investors included RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysios Capital, HealthCor Management and Boulder Ventures.
The company plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-HTN, for patients with uncontrolled hypertension.
Founded by Catalys Pacific and led by Jon Congleton, Chief Executive Officer, and BT Slingsby MD, PhD, MPH, Founder & Executive Chairman, Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapy for the treatment of hypertension.
Mineralys Therapeutics Closes $118M Series B Financing
Mineralys Therapeutics, Inc., a Philadelphia, PA-based clinical-stage biopharmaceutical company committed to developing a novel therapy for the treatment of hypertension, closed a $118m Series B financing
Capital Rx Closes $106M Series C Funding
Capital Rx, a New York-based health technology company, raised $106M in Series C funding.
The round was led by B Capital, with participation from General Catalyst, Transformation Capital and Edison Partners.
The company intends to use the funds to accelerate growth and expand operations.
Led by AJ Loiacono, CEO, Capital Rx aims to change the way prescription drugs are priced and patients are serviced. Its enterprise pharmacy platform JUDI™ connects every aspect of the pharmacy ecosystem in one system, plan build, implementation, claims adjudication, data exchange, prior authorization, client reporting, billing/reimbursement, member tools and more, enabling patient engagement and increasing efficiency to achieve the highest standards of clinical care.
Capital Rx Closes $106M Series C Funding - FinSMEs
Capital Rx, a New York-based health technology company, raised $106M in Series C funding
Code Biotherapeutics Raises $75 Million in Series A Financing
Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-viral delivery of genetic medicines, raised $75M in Series A funding.
The round was led by Northpond Ventures with participation from Amgen Ventures, Hatteras Venture Partners, UCB Ventures, New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, JDRF T1D Fund, UPMC Enterprises, and Takeda Ventures. As part of the financing, Diana Bernstein, Ph.D., Vice President at Northpond Ventures, will join Code Bio’s board of directors.
Led by CEO Brian P. McVeigh, Code Bio is a biotechnology company advancing genetic medicines to treat and potentially cure serious and life-threatening genetic diseases. By leveraging its novel non-viral multivalent synthetic DNA delivery platform, 3DNA®, Code Bio’s approach can overcome multiple challenges inherent with viral-based delivery approaches, including immunogenicity, size and delivery limitations, inability to re-dose and manufacturing complexity. The company is advancing an internal pipeline of therapies focused on serious and life-threatening diseases while also developing multiple collaborative partnerships to take forward additional programs in both rare and prevalent diseases.
The company intends to use the funds to advance its two lead programs in DMD and T1D toward IND-enabling studies, expand its pipeline and platform applications, and expand its manufacturing and operations.
Code Biotherapeutics Raises $75 Million in Series A Financing - FinSMEs
Code Biotherapeutics, a Greater Philadelphia, PA-based biotechnology company advancing targeted non-viral delivery of genetic medicines, raised $75M in Series A funding
Bicycle Health Raises $50M in Series B Funding
Bicycle Health, a Boston, MA-based provider of virtual opioid addiction treatment, raised $50m in Series B funding.
The round, which brought total funds raised to $83m, was led by InterAlpen Partners, with participation from existing investors Questa Capital, Frist Cressey Ventures, and City Light Capital.
The company intends to use the funds to continue growing the team of clinical and technology innovators, advance its virtual care platform, expand access to its care through strategic partnerships, and develop research into the efficacy and outcomes of its virtual, Medications for Addiction Treatment (MAT) model for patients at all steps of their OUD recovery journey.
Founded in 2017 by Ankit Gupta, CEO, Bicycle Health is a provider of virtual opioid addiction treatment, reducing OUD symptoms in over 15,000 patients and saving the healthcare system over $1.1 billion. The company currently offers the largest national coverage and is available across the most number of states, expanding into its 25th, Delaware, in May 2022.
Bicycle Health Raises $50M in Series B Funding
Bicycle Health, a Boston, MA-based provider of virtual opioid addiction treatment, raised $50m in Series B funding
ResMed buys German digital healthcare platform MEDIFOX DAN for $1 billion
Software and services investor Hg has sold German digital care platform MEDIFOX DAN to San Diego-based ResMed in a transaction valuing the business at an enterprise value of around $1 billion. The new acquisition will allow ResMed to expand its SaaS business footprint outside the U.S. and speed up the digital transformation of care in Germany.
German-based MEDIFOX DAN offers software solutions and services to care and therapy providers. Its core offering comprises digital solutions for resource and route planning, care planning and documentation, administration, and billing, as well as factoring and hosting services.
ResMed buys German digital healthcare platform MEDIFOX DAN for $1 billion - Tech.eu
The new acquisition will allow ResMed to expand its SaaS business footprint outside the U.S. and speed up the digital transformation of care in Germany
Wavemaker Three-Sixty Health Closes Fund II, at $64 Million
Wavemaker Three-Sixty Health, a Pasadena, CA-based venture fund focused on early-stage (primarily seed) healthcare disruptors, raised $64M in Fund II.
Fund II’s Limited Partners (LPs) include hundreds of healthcare organizations and prominent healthcare executives across the United States, as well as some international investors.
The vehicle aims to invest into 40-50 early-stage companies (U.S. and to a lesser extent international).
Led by John Nackel, PhD, Founder and General Partner, and Jay Goss, General Partner, Wavemaker Three-Sixty Health (Wavemaker 360) is a seed-stage healthcare pure-play venture firm focused on disruptors in the areas of health-tech, digital health, medical device, telehealth, artificial intelligence, pharma-tech, science and marketplaces. Wavemaker 360 discovers, vets and invests solely in healthcare startups at the seed funding stage. The firm connects its portfolio companies to a network of 300 Limited Partners (LPs), comprised of healthcare entities and executives in virtually every area of healthcare.
In addition to its healthcare-focused LP network, Wavemaker 360 also includes a Council of Strategic Advisors comprised of executive-level professionals spanning an array of verticals in the healthcare industry including health systems administration, provider economics, government sponsored healthcare, healthcare staffing, digital health and beyond.
Wavemaker Three-Sixty Health Closes Fund II, at $64 Million - FinSMEs
Wavemaker Three-Sixty Health, a Pasadena, CA-based venture fund focused on early-stage (primarily seed) healthcare disruptors, raised $64M in Fund II
Kairos Ventures Closes Third Fund at $58 Million
Kairos Ventures, a Los Angeles, CA-based early stage venture capital firm investing in physical and life sciences, closed its third fund, at $58M.
Fund III has made 27 investments in companies such as:
Vivodyne, a bioengineering company creating fully-vascularized human organoids (“organs-on-chip”) and can deploy them in fully automated instruments conducting thousands of experiments at a time; PteroDynamics, an aircraft design and manufacturing company that has developed and patented a unique drone with folding airplane wings; and Linnaeus, a development stage biotech company engaged in studying and developing treatments for cancer using the signaling from the female sex hormone as a protection against cancer. The remaining funds will be primarily used to support existing investments.
Founded in 2015 by Jim Demetriades, Kairos Ventures works closely with the world’s top patent producing universities and research institutions to identify and support the commercialization of transformative discoveries into sustainable and successful businesses.
